Lupin Pharmaceuticals Inc. has recalled 575,568 bottles of Cefdinir for Oral Suspension USP, a generic antibiotic used to treat bacterial infections. Approximately 287,784 bottles of the 125mg/5mL strength and 287,784 bottles of the 250mg/5mL strength are affected. The recall was initiated because the company received complaints that the medication became too thick after being mixed with water, which can lead to dosing inaccuracies or difficulty administering the drug. These products were distributed nationwide in 60mL and 100mL bottles and were available by prescription.
A thick or improperly formulated suspension can prevent the medication from being measured correctly, potentially leading to an underdose or overdose. If the drug is too thick to be poured or swallowed easily, the patient may not receive the full therapeutic dose required to treat their infection, potentially leading to treatment failure.
Return for refund and consult healthcare provider
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.